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ABSTRACT: THE ROLE OF HIPPO PATHWAY IN MITOSIS AND CANCER 
 
Xingcheng Chen, Ph.D. 
University of Nebraska, 2017 
Supervisor: Jixin Dong, Ph.D. 
The Hippo signaling pathway has been recently elucidated as a tumor suppressor 
pathway controlling cell proliferation and apoptosis. The core of this pathway is a kinase 
cascade which contains MST1/2 (Mammalian sterile 20-like kinase 1/2), LATS1/2 (large 
tumor suppressor 1/2) and downstream effector named Yes-associated protein (YAP). 
MST1/2 transduce their kinase activity mainly through directly phosphorylating LATS1/2. 
Once phosphorylated and activated, LATS1/2 subsequently phosphorylate and inhibit 
YAP from translocating to nucleus. Current studies involving the Hippo pathway focus on 
determining its oncogenic role in various organs/tissues. While those studies provide 
important insight into the tumor suppressor properties of this pathway, the underlying 
molecular mechanisms through which the Hippo components exert their 
oncogenic/suppressing function are poorly understood. Our study found that the adaptor 
protein Ajuba (recent found as a positive regulator of YAP oncogenic activity) and MST2 
(the core kinase in the Hippo pathway), are phosphorylated by CDK1 in mitosis via novel 
sites. We further characterized the phospho-regulation of Ajuba and MST2 in mitosis and 
examined the functional significance of the phosphorylation. Mutation of those 
phosphorylation sites impact cell proliferation in vitro and tumorigenesis in vivo.  
Our group has recently shown that the downstream effector of the Hippo pathway, 
YAP, is phosphorylated during mitosis and activated in a CDK1-dependent manner. In this 
study, we generated, for the first time, a doxycycline-inducible mouse model in which 
iv 
active YAP was specifically expressed in the pancreas. Interestingly, this mouse model 
develops pancreatic acinar-to-ductal metaplasia (ADM) in two weeks. Moreover, 
significant body weight loss and food intake decrease were observed after YAP induction 
in the pancreas, which are characteristics of cachexia. Cachexia is a wasting syndrome 
associated with typical types of cancer, particularly the gastrointestinal tract cancer and 
lung cancer. Among those cancer types, pancreatic ductal adenocarcinoma (PDAC) has 
the highest incidence of cancer cachexia. Therefore, our study suggests a potential role 
of YAP in pancreatic cancer-associated cachexia (CAC).  
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CHAPTER 1: AJUBA PHOSPHORYLATION BY CDK1 PROMOTES CELL 
PROLIFERATION AND TUMORIGENESIS* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The material presented in this chapter was previously published: Chen et al. J Biol Chem 2016; 
291(28): 14761-14772. 
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ABSTRACT 
Recent studies identified the adaptor protein Ajuba as a positive regulator of Yes-
associated protein (YAP) oncogenic activity through inhibiting large tumor suppressor 
(Lats1/2) core kinases of the Hippo pathway, which plays important roles in cancer. In this 
study, we define a novel mechanism for phospho-regulation of Ajuba in mitosis and its 
biological significance in cancer. We found that Ajuba is phosphorylated in vitro and in 
vivo by cyclin-dependent kinase 1 (CDK1) at Ser119 and Ser175 during the G2/M phase of 
the cell cycle. Mitotic phosphorylation of Ajuba controls the expression of multiple cell 
cycle regulators; however, it does not affect Hippo signaling activity, nor does it induce 
epithelial-mesenchymal transition (EMT). We further showed that mitotic phosphorylation 
of Ajuba is sufficient to promote cell proliferation and anchorage-independent growth in 
vitro and tumorigenesis in vivo. Collectively, our discoveries reveal a previously 
unrecognized mechanism for Ajuba regulation in mitosis and its role in tumorigenesis.  
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1.1. Introduction 
Genetic screens in Drosophila have discovered the Hippo pathway [1] and extensive 
studies have demonstrated important roles for Hippo signaling in tissue homeostasis, stem 
cell function, and cancer biology [2-5]. Protein kinases MST1/2 (together with the adaptor 
protein WW45) and Lats1/2 (with the regulatory subunit Mob1) form the core complexes 
in the Hippo pathway and these proteins regulate each other through phosphorylation. 
This core kinase signaling subsequently phosphorylates and inactivates the downstream 
effectors, oncoproteins YAP and TAZ, by sequestering them in the cytoplasm and 
promoting ubiquitination-dependent degradation [4, 6]. During past years, many regulators 
and input signals have been identified that influence Hippo-YAP signaling activity, such 
as the cell polarity and adherens junctions proteins, mechanical force, actin cytoskeleton 
[6-8], hypoxia [9], energy stress [10, 11], and mitosis/cytokinesis stress [12-15]. The 
downstream effectors YAP/TAZ also cross-talk with, or function as, mediators of many 
other signaling pathways, such as the GPCRs, Wnt/ β-catenin, TGF-β/SMAD, EGF, 
Notch, Hedgehog, and KRas/MAPK pathways [16]. 
A previous study identified Drosophila jub (Djub, orthologous to Ajuba proteins in 
mammals) as a negative regulator of the Hippo pathway [17]. Djub promotes Yki 
(Drosophila ortholog of YAP/TAZ) activation through interacting with, and inhibiting, Warts 
(Drosophila ortholog of Lats1/2) kinase, and this function/mechanism appears to be 
conserved in mammalian cells [17]. Subsequent studies revealed that Ajuba functions as 
an adaptor protein that links EGFR-MAPK signaling to the Hippo pathway in both 
Drosophila and mammals [18]. Furthermore, Djub/Ajuba are also required for JNK-
mediated activation of Yki/YAP, implying a conserved link between JNK signaling and 
Hippo pathway [19]. Interestingly, cytoskeletal tension modulates organ growth through 
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Yki in a Djub-dependent manner in Drosophila, although such a link in mammalian cells 
has not been identified [20]. 
Ajuba family proteins, including Ajuba, LIM-domain containing protein 1 (LIMD1), and 
Wilms tumor 1 interacting protein (WTIP), are adaptor/scaffold proteins with three LIM 
domains at their C termini. The LIM domains interact with other proteins in various 
subcellular locations to exert the biological functions of Ajuba proteins [21]. The Ajuba 
family is involved in many cellular processes such as cell-cell adhesion, gene transcription, 
cell proliferation, cell migration, and mitosis/cytokinesis [21]. Interestingly, several studies 
also suggest that Ajuba family proteins function as potential tumor suppressors or 
oncoproteins [22-26]. Some reports indicate that Ajuba is a critical member of the mitotic 
machinery. For example, Ajuba activates Aurora-A kinase to recruit the CDK1-cyclin B 
complex to centrosomes, and it contributes to mitotic entry [27]. Similarly, Ajuba 
associates with Lats2 at centrosomes during mitosis and regulates the integrity of the 
spindle apparatus [28]. Ajuba is also a microtubule-associated protein and plays a role in 
metaphase-anaphase transition through interactions with Aurora-B and BubR1 at 
kinetochores [29]. Collectively, these studies suggest an important role of Ajuba in mitosis, 
and indicate that Ajuba may exert its oncogenic or tumor suppressive function via 
dysregulation of mitosis. Ajuba has been observed to be phosphorylated by Aurora-A [27] 
and Lats2 [28] in mitosis; however, the phosphorylation site(s) and its biological function 
have remained elusive. 
We have recently investigated how the Hippo pathway (core members and their 
regulators) is regulated in mitosis. We have shown that KIBRA (an upstream regulator of 
the Hippo pathway) [30, 31], YAP [12, 13], and TAZ [15] are phosphorylated by mitotic 
kinases. Importantly, mitotic phosphorylation of YAP/TAZ is critical for proper mitotic 
progression and for their oncogenic activity in cancer cells [12, 13, 15]. These studies 
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prompted us to further examine whether other components or regulators of the Hippo 
pathway are regulated by phosphorylation during mitosis. In this study, we found that 
many of the Hippo members/regulators, including Ajuba, are indeed phosphorylated 
during antimitotic drug-induced G2/M phase arrest. We characterized the phospho-
regulation of Ajuba in mitosis, and identified CDK1 as a major kinase for mitotic-
phosphorylation of Ajuba. We further examined the functional significance of the 
phosphorylation and found that mitotic-phosphorylation promotes the oncogenic activity 
of Ajuba independently of the Hippo pathway, suggesting a novel mechanism that 
regulates Ajuba in cancer cells. 
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1.2. Materials and Methods 
1.2.1.  Cell Culture and Transfection  
HEK293T, HEK293GP, and HeLa cell lines were purchased from American Type 
Culture Collection (ATCC) and cultured as ATCC instructed. HPNE cells were provided 
by Dr. Michel Ouellette (University of Nebraska Medical Center, who established and 
deposited this cell line at ATCC) and were cultured as described [32].The cell lines were 
authenticated at ATCC and were used at low (<25) passages. The colon cancer cell line 
RCA was a gift from Dr. Michael Brattain (University of Nebraska Medical Center) [33] and 
was maintained in minimal essential medium supplemented with 10% FBS and antibiotics. 
Attractene (Qiagen) was used for transient overexpression of proteins in HEK293T and 
HEK293GP cells following the manufacturer’s instructions. Ectopic expression of Ajuba or 
its mutants in HPNE cells was achieved by a retrovirus-mediated approach. Retrovirus 
packaging, infection, and subsequent selection were done as we have described 
previously [34]. Nocodazole (100ng/ml for 16h) and Taxol (100 n M for 16h) (Selleck 
Chemicals) were used to arrest cells in G2/M phase unless otherwise indicated. VX680 
(Aurora-A,-B, and-C inhibitor), ZM447439 (Aurora-B,-C inhibitor), BI2536 (Plk1 inhibitor), 
Purvalanol A (CDK1/2/5 inhibitor), SB216763 (GSK-3β inhibitor), Rapamycin (mechanistic 
target of rapamycin inhibitor), and MK2206 (Akt inhibitor) were also from Selleck 
Chemicals. RO3306 (CDK1 inhibitor) and Roscovitine (CDK1/2/5 inhibitor) were from 
ENZO Life Sciences. MK5108 (Aurora-A inhibitor) was from Merck. Kinase inhibitors for 
MEK-ERK (with U0126), p38 (with SB203580), and PI-3K (with LY294002) were from LC 
Laboratory. All other chemicals were either from Sigma or ThermoFisher. 
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1.2.2. Expression Constructs 
The human Ajuba cDNA clone (ID HSCD00323154) was obtained from Harvard 
Medical School. To make the retroviral or GFP-tagged Ajuba expression constructs, the 
above full-length cDNA was cloned into the MaRXTM IV [34] or pEGFP-C1 vector 
(Clontech), respectively. HA-FRMD6 (HA-EX) was made by cloning FRMD6 cDNA [35] 
into the pcDNA3.1-HA vector [34]. Myc-Lats2 has been described [34]. Point mutations 
were generated by the QuikChange Site-directed PCR mutagenesis kit (Stratagene) and 
verified by sequencing.  
1.2.3. Tet-On-inducible Expression System 
Tet-On-inducible shRNA vectors against Ajuba were purchased from GE 
Healthcare/Dharmacon (V3THS-343741). To make the shRNA-resistant (shR) Ajuba 
cDNA, the target sequence (5’-ACCGACTACCACAAAAATT-3’) was changed into 5’-
ACgGAtTAtCAtAAAAATT-3’ by PCR mutagenesis. The mutated Ajuba cDNA was then 
cloned into the Tet-All vector [36] to generate a Tet-On-inducible shR-Ajuba construct. 
Ajuba down-regulationin RCA cells was achieved by lentivirus-mediated Ajuba shRNA 
expression in a doxycycline-dependent manner. Lentivirus generation and infection were 
performed as described with slight modifications [37]. The transduced cells were selected 
with puromycin (1 μg/ml) to establish pooled cell lines. The cell line in which the lack of 
Ajuba expression was confirmed (Tet-inducible knockdown) was then used for 
transduction/infection with virus expressing Tet-All-shR Ajuba or mutant constructs. Cells 
were maintained in medium containing Tet system-approved fetal bovine serum (Clontech 
Laboratories). 
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1.2.4. Quantitative Real-time PCR 
Total RNA isolation, RNA reverse transcription, and quantitative real time-PCR were 
done as we have described previously [34].Cell proliferation analysis Cell numbers were 
monitored with an Invitrogen Countess automated cell counter after YAP was knocked 
down or overexpressed for 5 d. Trypan blue was used to identify and quantify viable cells. 
1.2.5. Recombinant Protein Purification and in Vitro Kinase Assay 
The GST-tagged Ajuba (amino acids 2–240, cloned in pGEX-5X-1) proteins were 
bacterially expressed and purified on GSTrap FF affinity columns (GE Healthcare) 
following the manufacturer’s instructions. To make His-tagged Ajuba (amino acids 2-468), 
the corresponding Ajuba cDNA was subcloned into the pET-28a vector (Novagen/EMD 
Chemicals). The proteins were expressed and purified on HisPurTM Cobalt spin columns 
(Pierce) following the manufacturer’s instructions. 
His-or GST-Ajuba (0.5-1 μg) was incubated with 5-10 units of recombinant 
CDK1/cyclin B complex (New England Biolabs) or 50-100 ng of CDK1/cyclinB 
(SignalChem) or HeLa cell total lysates (treated with DMSO or Taxol) in kinase buffer 
(New England Biolabs) in the presence of 5 μCi of [γ-32 P] ATP (3000 Ci/mmol, 
PerkinElmer Life Sciences). Phosphorylation (32P incorporation) was visualized by 
autoradiography followed by Western blotting or detected by phospho-specific antibodies. 
1.2.6. Antibodies 
The polyclonal Ajuba antibodies (4897) from Cell Signaling Technology were used for 
Western blotting throughout the study. Rabbit polyclonal phospho-specific anti-bodies 
against human Ajuba Ser119 and Ser175 were generated and purified by AbMart. The 
peptides used for immunizing rabbits were TAPAL-pS-PRSSF (Ser119) and DQRHG-pS-
9 
PLPAG (Ser175). The corresponding non-phosphorylated peptides were also synthesized 
and used for antibody purification and blocking assays. HA antibodies were from Sigma 
(H9658). Anti-β-actin (SC-47778), anti-GFP (SC-9996), and anti-cyclin B (SC-752) 
antibodies were from Santa Cruz Biotechnology. Aurora-A (A300-070A), glutathione S-
transferase (GST) (A190-122A), His (A190-114A), MST1 (A300-465A), MST2 (A300-
467A), Lats1 (A300-478A), Aurora B (A300-431A), BUB1 (A300-373A), and BubR1 
(A300-386A) antibodies were from Bethyl Laboratories. Phospho-Thr288 /Thr232 /Thr198 
Aurora-A/B/C (2914), Phospho-Histone H3 (Ser10)  (3377), phospho-Ser127 YAP (4911), 
phospho-Ser909 Lats1 (9157), Lats2 (5888), WW45 (3507), TAZ (4883), TEAD1 (12292), 
NF2 (6995), Vimentin (5741), E-cadherin (3195), PTPN14 (13808), LIMD1 (13245), Zyxin 
(3553), CDC25C (4688), CDK1 (9116), phos-pho-Tyr15 CDK1 (9111), cyclin A (4656), 
cyclin E (4132), p53 (2527), MAD2 (4636), phospho-Ser795 Rb(9301), and phospho-Ser642 
Wee1 (4910) antibodies were also from Cell Signaling Technology. The monoclonal 
antibody against KIBRA has been described [34]. Rabbit anti-α-tubulin (Abcam, 15246) 
and mouse anti-β-tubulin (Sigma, T5293) antibodies were used for immunofluorescence 
staining. 
1.2.7. Phos-tag and Western Blot Analysis 
Phos-tag TM was obtained from Wako Pure Chemical Industries, Ltd. (30493521) and 
used at 20 μM (with 100μM MnCl2) in 6 or 8% SDS-acrylamide gels. Prior to transferring, 
the gels were equilibrated in transfer buffer containing 10 m M EDTA, two times, each for 
10 min. The gels were then soaked in transfer buffer (without EDTA) for another 10 min. 
Western blotting, immunoprecipitation, and λ-phosphatase treatment assays were done 
as previously described [31]. 
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1.2.8. Immunofluorescence Staining and Confocal Microscopy 
Cell fixation, permeabilization, fluorescence staining, and microscopy were done as 
previously described [38]. For peptide blocking, a protocol from the Abcam website was 
used, as we previously described [12]. 
1.2.9. Colony Formation and Cell Proliferation Assays 
Colony formation assays in soft agar were performed as described [32]. Cells 
(10,000/well) were seeded in a 6-well plate and colonies were counted by ImageJ online. 
For cell proliferation assays, cells (100,000/well) were seeded in a 6-well plate in triplicate. 
Cells were counted by a hemacytometer and proliferation curves were made based on the 
cell number in each well from three independent experiments. 
1.2.10. Animal Studies 
For in vivo xenograft studies, RCA cells (with Tet-shRNA-Ajuba) expressing Tet-All-
shR-Ajuba or Tet-All-shR-Ajuba-2A (non-phosphorylatable mutant) (2.0 X 106 cells each 
line) were subcutaneously injected into the left or right flank of 6-week-old male athymic 
nude mice (Ncr-nu/nu, Harlan). Ten animals were used per group. Tumor sizes were 
measured once a week using an electronic caliper starting at 3 weeks after injection (when 
tumors in the Ajuba-2A group are palpable). Tumor volume (V) was calculated by the 
formula: V = 0.5 X length X width2 [32]. Mice were euthanized at 6 weeks post-injection 
and the tumors were excised for subsequent analysis. The animals were housed in 
pathogen-free facilities. All animal experiments were approved by the University of 
Nebraska Medical Center Institutional Animal Care and Use Committee.  
 
 
11 
1.2.11. Statistical Analysis 
Statistical significance was analyzed using a two-tailed, unpaired Student’s t test. 
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1.3. Results 
1.3.1. Ajuba Family Proteins Are Phosphorylated during Antimitotic Drug-induced 
G2/M Arrest 
To further explore whether members of the Hippo pathway are regulated by 
phosphorylation during mitosis, we examined the phosphorylation status of the Hippo 
pathway proteins during G2/M arrest induced by Taxol or Nocodazole. As shown in Fig.1-
1A, consistent with previous reports, there was a dramatic up-shift of Lats1 and Lats2 
mobility (due to mitotic phosphorylation) [39] during Taxol or Nocodazole treatment (Fig. 
1-1A). As expected, the mobility of KIBRA, YAP, and TAZ were all significantly retarded 
due to phosphorylation during G2/M arrest (Fig. 1-1A) [12, 15, 30, 31]. Taxol or 
Nocodazole treatment did not cause any evident change in the mobility/phosphorylation 
for PTPN14, NF2, or EX (which are all upstream regulators of the Hippo-YAP pathway), 
for WW45 or TEAD1 (Fig. 1-1A). Interestingly, MST2, but not MST1, was phosphorylated 
during G2/M arrest (Fig. 1-1A). One of the most prominent changes we observed was the 
striking mobility up-shift of the Ajuba and Zyxin family proteins including Ajuba, LIMD1, 
and Zyxin (Fig. 1-1A). In this study, we have chosen to focus on Ajuba, and so we further 
investigated its phosphorylation status. λ-Phosphatase treatment completely converted all 
slow-migrating bands to fast-migrating bands, confirming that the mobility shift of Ajuba 
during G2/M arrest is caused by phosphorylation (Fig. 1-1B).  
1.3.2. Identification of the Corresponding Kinase for Ajuba Phosphorylation 
Next, we used various kinase inhibitors to identify the candidate kinase for Ajuba 
phosphorylation. In contrast to the findings in a previous study [27], our data demonstrated 
that inhibition of Aurora-A (with MK5108) or Aurora-A, -B, and -C (with VX680) kinases 
only mildly reduced Ajuba phosphorylation (Fig.1-1C). Addition of BI2536 (an inhibitor for 
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mitotic kinase Plk1) had no effect on the Ajuba mobility shift/phosphorylation (Fig. 1-1C). 
Interestingly, treatments with RO3306 (CDK1inhibitor), Roscovitine (inhibits CDK1/2/5), or 
Purvalanol A (CDK1/2/5 inhibitor) almost completely reverted the mobility 
shift/phosphorylation (Fig. 1-1C, lanes 7-9). CDK1 is a well-known mitotic kinase. These 
data suggest that CDK1 is likely the corresponding kinase for Ajuba phosphorylation 
induced by Taxol or Nocodazole treatments. Inhibition of MEK-ERK kinases ( with U0126 
), p38 ( with SB203580 ),GSK-3β ( with SB216763 ), mechanistic target of rapamycin (with 
rapamycin), PI-3K ( with LY294002 ), or Akt ( MK2206 ) failed to alter the phosphorylation 
of Ajuba during G2/M arrest (data not shown). 
1.3.3. CDK1 Phosphorylates Ajuba in Vitro 
To determine whether CDK1 kinase can directly phosphorylate Ajuba, we performed 
in vitro kinase assays with His-tagged Ajuba proteins as substrates. Fig. 1-2A shows that 
Taxol-treated mitotic lysates robustly phosphorylated Ajuba and that addition of RO3306 
or Purvalanol A greatly reduced phosphorylation of His-Ajuba (Fig. 1-2A). As expected, 
purified CDK1-cyclin B kinase complex phosphorylated His-Ajuba proteins in vitro (Fig. 1-
2B). These results indicate that CDK1 directly phosphorylates Ajuba in vitro.  
1.3.4. CDK1-Cyclin B Complex Phosphorylates Ajuba at Ser 119 in Vitro and in 
Cells 
CDK1 phosphorylates substrates at a minimal proline-directed consensus sequence 
[40]. Ajuba contains a total of 6 (S/T) P motifs (Thr30, Ser119, Ser137, Ser175, Ser196, 
and Ser237). Interestingly, two of them (Ser119 and Ser175) were identified as mitotic 
phosphorylation sites by previous phospho-proteomic studies [41] and mutating these two 
sites to alanine abolished the 32P incorporation in His-Ajuba, suggesting that Ser119 and 
Ser175 are the main CDK1 sites in Ajuba in vitro (Fig. 1-2C). Ser119 and Ser175 are 
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highly conserved in vertebrates (Fig. 1-2D). Therefore, these two sites were chosen for 
further study.  
We have generated phospho-specific antibodies against Ser119 and Ser175. In vitro 
kinase assays demonstrated that CDK1 readily phosphorylates Ajuba at Ser119 (Fig. 1-
2E). Very weak signal was detected when the phospho-Ser175 antibody was used under 
these conditions (data not shown). Addition of RO3306 or mutating Ser119 to alanine 
abolished the phosphorylation (Fig. 1-2E). These data suggest that CDK1 phosphorylates 
Ajuba at Ser119 in vitro. Taxol treatment significantly increased the phosphorylation of 
Ser119 on endogenous Ajuba (Fig. 1-2F). Using inhibitors for CDK1 kinase, we 
demonstrated that phosphorylation of Ajuba Ser119 is CDK1 kinase dependent (Fig. 1-
2F). The signal of Ajuba Ser119 during Taxol treatment was significantly reduced in Ajuba 
knockdown cells, confirming the specificity of the phospho-Ser119 antibody (Fig. 1-2G). 
Taxol treatment also increased the phosphorylation of Ser119 on transfected Ajuba, and 
the signal was abolished by mutating Ser119 to alanine (Fig. 1-2H), suggesting that these 
antibodies specifically recognize phosphorylated Ajuba. Taken together, these 
observations indicate that Ajuba is phosphorylated at Ser119 by CDK1 in cells during 
antimitotic drug-induced G2/M arrest. 
1.3.5. CDK1/Cyclin B Mediates Ajuba Phosphorylation at Ser119 and Ser175 in 
Cells 
We next performed immunofluorescence microscopy with these phospho-specific 
antibodies. Both antibodies against Ser119 and Ser175 detected strong signals in 
Nocodazole-arrested prometaphase cells (Fig. 1-3, A-C, white arrows). The sign was 
always very low or not detectable in interphase cells (Fig. 1-3, A-C, yellow arrows). The 
specificity of the antibodies was further confirmed by peptide blocking assays. Phospho-
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peptide, but not control non-phosphopeptide, incubation completely blocked the signal, 
suggesting that these antibodies specifically recognize Ajuba only when it is 
phosphorylated (Fig. 1-3, A and B). Again, addition of RO3306 or Purvalanol A largely 
diminished the signals detected by p-Ajuba Ser119 and Ser175 antibodies in Nocodazole-
treated prometaphase cells, further indicating that the phosphorylation is CDK1 dependent 
(Fig. 1-3, A and B, low panels). 
1.3.6. Ajuba Phosphorylation Occurs during Normal Mitosis 
To determine whether phosphorylation of Ajuba occurs during normal mitosis, we 
collected samples from a double thymidine block and release [38] and performed 
immunofluorescence staining on cells in different cell-cycle phases. Consistent with Fig. 
1-3, a very weak signal was detected in interphase or cytokinesis cells (Fig. 1-4, A and B). 
The p-Ajuba Ser119 signal was increased in prophase and the strongest signal was 
detected in prometaphase/metaphase cells. The signal was then again weakened during 
telophase (Fig. 1-4, A and B). Similar staining patterns were observed with p-Ajuba Ser175 
antibody (Fig. 1-4, C and D). After being released from the double thymidine block, cells 
enter into mitosis at 10-12 h revealed by increased Phospho-Histone H3 (Ser10)  and the 
p-Ajuba Ser119 signal was also increased in these cells (Fig. 1-4E). These results indicate 
that Ajuba phosphorylation occurs dynamically during normal mitosis. 
1.3.7. Mitotic Phosphorylation of Ajuba Impacts Cell Cycle Regulators without 
Affecting YAP Activity 
Ajuba was shown to affect the Hippo-YAP signaling activity through interacting with 
Lats1/2 kinase [17-19]. We confirmed that the association between Ajuba and Lats2 was 
readily detected (Fig. 1-5A). Non-phosphorylatable (Ajuba-2A, S119A/S175A) or a 
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phosphomimetic (Ajuba-2D, S119D/S175D) mutant has similar binding affinity with Lats2 
as wild type Ajuba (Fig. 1-5A), suggesting that Ajuba phosphorylation does not impact its 
association with Lats2. YAP Ser127 phosphorylation, Lats activity (revealed by phospho-
Ser909 ), and the levels of YAP and Lats proteins were not significantly altered when Ajuba 
was overexpressed (in HPNE, immortalized pancreatic epithelial cells) or knocked down 
(in RCA colon cancer cells) (Fig. 1-5B). Epithelial-mesenchymal transition is a critical 
process during development, wound healing, and stem cell behavior, and contributes 
pathologically to cancer progression and metastasis [42]. Several members of the Hippo-
YAP signaling regulate epithelial-mesenchymal transition. However, manipulation of 
Ajuba expression failed to influence the expression of the epithelial-mesenchymal 
transition markers (Fig. 1-5B). In line with these observations, the targets expression of 
YAP was not affected by Ajuba expression in HPNE and RCA cells (Fig. 1-5, C and D). 
These results suggest that mitotic phosphorylation of Ajuba does not affect YAP activity 
and that Ajuba influences Hippo-YAP activity in a context-dependent manner. 
We further determined whether Ajuba/mitotic phosphorylation affects cell cycle 
regulators. Interestingly, the expression of several genes (including CDC25C, BUB1 and 
phosphorylated Wee1) was increased upon Ajuba knockdown in RCA cells (Fig.1-5E). 
Moreover, re-expression of wild type Ajuba, but not the Ajuba-2A mutant, rescued the 
phenotype (Fig. 1-5E). These observations suggest that Ajuba and its phosphorylation 
may have a role in cell cycle progression through regulation of the expression of cell cycle 
regulators. 
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1.3.8. Mitotic Phosphorylation of Ajuba Is Required for Cell Proliferation and 
Anchorage-independent Growth 
  Next we asked what the biological significance of mitotic phosphorylation of Ajuba is. 
To address this question, we first established HPNE cell lines stably expressing Ajuba or 
non-phosphorylatable Ajuba mutant (Ajuba-2A) (Fig. 1-6A). Interestingly, overexpression 
of Ajuba significantly increased cell proliferation when compared with control cells. 
However, cells expressing Ajuba-2A proliferated at a rate similar to that of control cells, 
suggesting that mitotic phosphorylation of Ajuba promotes cell proliferation (Fig. 1-6B). 
Ectopic expression of Ajuba (wild type or 2A or 2D) was not sufficient to stimulate 
anchorage-independent growth in soft agar in HPNE cells (data not shown). We further 
determined the impact of mitotic phosphorylation of Ajuba in cancer cells. We established 
RCA cell lines in which the endogenous Ajuba was replaced with shRNA-resistant Ajuba 
or Ajuba-2A in a Tet-inducible manner (Fig. 1-6C). Without doxycycline induction, these 
cell lines express similar levels of endogenous Ajuba proteins (Fig. 1-6C, left 4 lanes) and 
no proliferation or other differences were detected among these cells. Addition of 
doxycycline to the cell culture medium induced endogenous Ajuba knockdown and 
expression of shRNA-resistant Ajuba or its non-phosphorylatable mutant (Fig. 1-6C, right 
4 lanes). Consistent with the Ajuba overexpression results in HPNE cells, knockdown of 
Ajuba in RCA cells decreased proliferation, and importantly, expression of wild type Ajuba, 
but not the non-phosphorylatable mutant Ajuba-2A, completely rescued the cell 
proliferation defects (Fig. 1-6D). Furthermore, Ajuba knockdown also significantly 
decreased anchorage-independent growth in soft agar, and again, re-expression of Ajuba-
2A failed to rescue the defects, whereas wild type Ajuba did (Fig. 1-6, E and F). These 
data suggest that mitotic phosphorylation is essential for Ajuba to promote cell proliferation 
and anchorage-independent growth. 
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1.3.9. Mitotic Phosphorylation of Ajuba Is Required for Tumorigenesis 
  We next evaluated the influence of Ajuba and its mitotic phosphorylation on tumor 
growth in animals. RCA cells in which the endogenous Ajuba was replaced with shRNA- 
resistant wild type Ajuba or Ajuba-2A (Fig. 1-6C) were subcutaneously inoculated into 
immunodeficient mice. Interestingly, tumors from mice harboring Ajuba-2A-expressing 
cells tended to be smaller when compared with those from mice injected with Ajuba-
expressing cells (Fig. 1-7A and B). Histopathological examination revealed no significant 
differences among these tumors (Fig. 1-7C). Consistent with Fig. 1-5E, CDC25C 
expression was higher in Ajuba-2A-expressing tumors than Ajuba-WT tumors (Fig. 1-7C). 
Western blotting analysis confirmed the phosphorylation status of Ser119, and verified that 
Ajuba (wild type or 2A) expression levels were similar in most of these tumors (Fig. 1-7D). 
These results support the hypothesis that mitotic phosphorylation is essential for Ajuba 
promoted tumor growth in vivo. 
  A previous report showed that Ajuba was up-regulated in colon cancer cell lines and 
tumors [22]. We further analyzed the expression of Ajuba in published data and confirmed 
that the mRNA levels of Ajuba were significantly increased in colon tumors compared with 
normal colon (Fig. 1-7, E–H). Together, these observations indicate that Ajuba functions 
as a tumor-promoting regulator in colon cancer in a mitotic phosphorylation-dependent 
manner. 
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1.4. Discussion 
Ajuba family proteins (Ajuba, LIMD1, and WTIP) play roles in various cellular 
processes, and one of the most studied areas is the role of Ajuba protein in mitosis. Ajuba 
is required for mitotic entry in coordination with Aurora-A kinase and is co-localized at 
centrosomes with Aurora-A, CDK1/cyclin B [27], and Lats2 [28] during G2/mitosis. 
Interestingly, Ajuba protein became phosphorylated in mitotic cells; however, there are 
differing reports regarding the kinase that contributes to this mitotic phosphorylation. 
Hirota et al. [27] showed that Aurora-A directly phosphorylated Ajuba in vitro but did not 
investigate whether Ajuba phosphorylation is Aurora-A dependent in cells. Another report 
suggested that Lats2 contributed to Ajuba phosphorylation during mitosis [28]. The current 
study provided evidence that CDK1 is the major kinase responsible for Ajuba 
phosphorylation and that CDK1 phosphorylates Ajuba in vitro and in cells during mitosis, 
adding a new layer of regulation for Ajuba during mitosis. Our data do not exclude the 
possibility that Aurora-A and Lats2 kinases can phosphorylate Ajuba in cells as well. 
Future studies are needed to further define the mitotic phosphorylation (phosphorylation 
sites and their biological function) of Ajuba by Aurora-A and/or Lats2. Of note, several 
large scale proteomic studies have identified Ser119 and Ser175 as mitotic phosphorylation 
sites and both sites fit the CDK1-phosphorylation consensus sequence [41]. 
In Drosophila, Djub promotes cell proliferation and inhibits apoptosis by regulating 
Hippo-Yki activity [17]. Consistent with these observations, our data further confirm that 
Ajuba is a positive regulator for cell proliferation and anchorage-independent growth in 
pancreatic and colon cancer cells (Fig. 1-6). Furthermore, Ajuba also promotes migration 
and invasion in colon cancer cells [22]. Interestingly, whereas these studies clearly 
showed that Ajuba promotes cell proliferation, Ajuba was shown to suppress malignant 
mesothelioma cell proliferation [23], suggesting a cell type-specific role of Ajuba in cancer 
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cells. In line with a role of Ajuba in cancer, recent large scale genomic studies found that 
the Ajuba gene is mutated in 7% of esophageal squamous cell carcinomas [24, 25] and 
Ajuba is overexpressed in colon cancer patients [22]. Our current study further 
demonstrates that mitotic phosphorylation of Ajuba by CDK1 is critical for its biological 
function, suggesting that there is a link between the role of Ajuba in cancer and its mitotic 
regulation and that Ajuba may exert its role in cancer through deregulation in mitosis. 
Together, these studies suggest that Ajuba may play a role in tumorigenesis, although 
further confirmation will require genetic animal models. Ajuba is not essential for embryo 
development and Ajuba knock-out mice have no obvious phenotypes [43]. These 
observations suggest that Ajuba may function as a fine regulator in tumorigenesis and 
needs an additional allele product to promote/inhibit tumor cell growth. However, knock-
out of the Ajuba allele has not been combined with any other oncogenes or tumor 
suppressors including ones in the Hippo-YAP pathway. In addition, since there is 
functional redundancy and overlapping expression within the Ajuba family proteins [21], 
clearly defining the biological role of Ajuba in tumorigenesis may be even more 
challenging. 
Mitotic aberrations cause genomic/chromosome instability, which is characteristic of 
human malignancy [44]. Several reports showed that the Hippo pathway plays important 
roles in maintaining normal mitosis and suggest a mechanism through which the Hippo 
tumor suppressor pathway exerts its function. For example, loss of core tumor 
suppressors in the Hippo pathway (including Lats2, MST1/2, Mob1, and WW45) leads to 
severe defects in multiple mitotic processes [45-47]. Accordingly, we recently reported that 
overexpression of active YAP [12, 13] or TAZ [15] is sufficient to trigger mitotic defects, 
including centrosome amplification, spindle disorganization, chromosome misalignment, 
and subsequent aneuploidy. Interestingly, we also found that several Hippo core members 
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(Lats1, Lats2, and MST2) (Fig. 1-1) or their upstream regulator (KIBRA) [30, 31] or 
downstream effectors ( YAP and TAZ ) [12, 13, 15] are phosphorylated during mitosis. 
Importantly, mitotic phosphorylation is critical for their oncogenic or tumor suppressive 
functions [12, 13, 15]. These observations suggest that in addition to their expression 
levels, the phosphorylation status of these proteins must also be finely controlled, adding 
another layer of regulation for Hippo-YAP activity during tumorigenesis. Such studies may 
provide additional insights into the underlying mechanisms of Hippo-YAP signaling in 
cancer. Thus, we extended our studies to other Hippo regulators and we found that the 
Ajuba/Zyxin family proteins (Ajuba, LIMD1, and Zyxin) are also phosphorylated during 
antimitotic drug-induced mitotic arrest (Fig. 1-1). Zxyin was previously shown to be 
phosphorylated and played a role in mitosis; however, the phosphorylation sites, 
corresponding kinase, and their functional significance remain elusive [48]. Although these 
proteins are structurally and functionally related, sites analogous to Ajuba Ser119 and 
Ser175 do not exist on LIMD1 and Zyxin. Additionally, the role of LIMD1 and its regulation 
in mitosis also remain to be defined. Addressing these questions will not only help 
understand the cellular function of these proteins in mitosis, but also provide insights into 
their biological significance and underlying mechanisms in cancer development. 
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Figure 1-1. CDK1-dependent phosphorylation of Ajuba during G2/M arrest. 
(A) HeLa cells were treated with DMSO, Taxol (100 nM for 16 h), or Nocodazole (Noco, 
100 ng/ml for 16h). Total cell lysates were probed with the indicated antibodies against 
Hippo components on Phos-tag SDS-polyacrylamide gels (see “Experimental 
Procedures”). O and * mark the non-phosphorylated and phosphorylated proteins, 
respectively. (B) HeLa cells were treated with Taxol as indicated and cell lysates were 
further treated with (+) or without (-) λ-phosphatase (ppase). Total cell lysates were probed 
with anti-Ajuba antibody. (C) HeLa cells were treated with Taxol together with or without 
various kinase inhibitors as indicated. VX680 (2 μM ), MK5108 (10 μM ), ZM447439(1 
μM ), RO3306( 5 μM ), Roscovitine (30 μM ), Purvalanol A ( 10 μM ), and BI2536 (100 
nM ) were used. Inhibitors were added (with MG132 to prevent cyclin B from degradation 
and cells from exiting from mitosis) 1 - 2 h before harvesting the cells. Total cell lysates 
were subjected to Western blotting with the indicated antibodies. 
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Figure 1-2. Ajuba is phosphorylated by CDK1 in vitro and in cells 
(A) In vitro kinase assays using HeLa cell lysates to phosphorylate recombinant His-Ajuba. 
Asy,asynchronized; Tax, Taxol-treated. Total cell lysates were probed with cyclin B and 
β-actin antibodies. RO3306 (5 μM) or PurvalanolA (10 μM) was used to inhibit CDK1 
kinase activity. (B) In vitro kinase assays with purified CDK1/cyclin B complex. RO3306 (5 
μM) was used to inhibit CDK1 kinase activity. (C) In vitro kinase assays with purified 
CDK1/cyclin B complex. 2A, S119A/S175A. (D) Conservation of the mitotic 
phosphorylation sites of Ajuba. (E) In vitro kinase assays were done as in B except anti-
phospho-Ajuba Ser119 antibodies were used. (F) HeLa cells were treated with Taxol 
together with or without various kinase inhibitors as indicated. Inhibitors were added (with 
MG132 to prevent cyclin B from degradation and cells from exiting from mitosis) 1h before 
harvesting the cells. Total cell lysates were subjected to Western blotting with the indicated 
antibodies. (G) RKO colon cancer cells expressing Tet-control shRNA or Tet-shRNA 
Ajuba ( #1 and #2 ) in the presence of doxycycline (1μg/ml for 2 days ) were treated with 
(+) or without (-) Taxol and total cell lysates were subjected to Western blotting with the 
indicated antibodies. (H) HEK293T cells were transfected with GFP-Ajuba or GFP-Ajuba 
mutants. At 32h post-transfection, the cells were treated with Taxol for 16 h. The 
immunoprecipitates (with GFP antibodies) were probed with anti-phospho-Ajuba and 
subsequent anti-GFP antibodies. Total cell lysates before immunoprecipitation were also 
included (cyclin B and β-actin). 
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Figure 1-3. CDK1 mediates the phosphorylation of Ajuba at Ser119 and Ser175 during 
G2/M phase arrest. 
(A) HeLa cells were treated with Nocodazole for 8h and then fixed. Before the cells were 
stained with phospho-specific antibody against Ser119 of Ajuba, the cells were pre-
incubated with PBS (no peptide control), or non-phosphorylated (control) peptide, or the 
phosphorylated peptide used for immunizing rabbits. CDK1 inhibitors RO3306 (5μM) or 
Purvalanol A (10μM) together with MG132 (25 μM) were added 2 h before the cells were 
fixed (bottom two rows). (B) Experiments were done similarly as in A with phospho-specific 
antibody against Ser175 of Ajuba. (C) HeLa cells were treated and stained with phospho-
specific antibodies as in A and B. An X63 oil objective lens was used to view fewer cells 
in a field. P-H3 S10 was used as a mitotic marker. White and yellow arrows mark some of 
the prometaphase cells and the interphase cells, respectively. 
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Figure 1-4. Ajuba is phosphorylated at Ser119 and Ser175 during unperturbed mitosis. 
(A-B) HeLa cells were synchronized by a double thymidine (DT) block and release 
method. Cells were stained with antibodies against p-Ajuba Ser119 or β-tubulin, or with 
DAPI. An X40 objective lens was used to view various phases of the cells in a field (B). 
(C-D) The experiments were done similarly as in A and B with p-Ajuba Ser175 antibodies. 
White and yellow arrows (in panels B and D) mark the metaphase and interphase cells, 
respectively. (E) HeLa cells were synchronized by a double thymidine block and release 
method. Total cell lysates were harvested at the indicated time points and subjected to 
Western blotting analysis.   
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Figure 1-5. Mitotic phosphorylation controls the expression of cell cycle regulators, 
but does not affect the Hippo-YAP activity. 
(A) HEK293T cells were transfected with various DNA plasmids as indicated. The 
immunoprecipitates (with Myc antibodies) were probed with anti-Ajuba and subsequent 
anti-Myc antibodies. Total cell lysates before immunoprecipitation were also included 
(Input). (B) Total cell lysates from various HPNE and RCA cell lines as indicated were 
probed with the indicated antibodies. HPNE cells were stably transduced with vector, 
Ajuba, Ajuba-2A, or Ajuba-2D. Tet-On-inducible Ajuba-knockdown cell lines expressing 
shRNA-resistant Ajuba or Ajuba-2A in RCA colon cancer cells were also established (see 
“Experimental Procedures“). 2A, S119A/S175A; 2D, S119D/S175D. (C-D) Quantitative 
RT-PCR for CTGF and Cyr61 in cell lines established in B. (E) Total cell lysates were 
harvested from RCA cell lines established in B and were subjected to Western blotting 
analysis with various cell cycle regulators. 
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Figure 1-6. Mitotic phosphorylation of Ajuba is required for cell proliferation and 
anchorage-independent growth. 
(A) HPNE cells stably expressing vector, Ajuba, or Ajuba-2A were established, and 
expression of Ajuba and Ajunba-2A were confirmed by Western blotting. 2A, S119A/S175 
A. (B) Cell proliferation assays with transduced HPNE cells established in A. Data were 
expressed as the mean ± S.D. of three independent experiments. ***, p<0.001;*, p<0.05 
(Ajuba-WT versus Ajuba-2A) (t test). (C) Establishment of Tet-On-inducible Ajuba-
knockdown cell lines expressing shRNA-resistant Ajuba or Ajuba-2A in RCA colon cancer 
cells (see “Materials and Methods“). Cells were kept on Tet-approved FBS and 
doxycycline was added (1 μg/ml) to the cells 2 days prior to the experiments. (D) Cell 
proliferation assays in RCA cells established in C in the presence of doxycycline (DOX). 
Data were expressed as the mean ± S.D. of three independent experiments. Red asterisks 
mark the comparisons between shControl and shAjuba. Green asterisks indicate the 
comparisons between Tet-Ajuba-WT and Tet-Ajuba-2A. ***, p<0.001;**, p<0.01;*, p<0.05 
(t test). (E-F), colony assays in soft agar to assess anchorage-independent growth of RCA 
cells established in C in the presence of doxycycline. Data were expressed as the mean 
± S.D. of three repeats (E) and representative images were shown (F). ***, p<0.001;**, p 
<0.01 (t test).   
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Figure 1-7. Ajuba phosphorylation is essential for tumorigenesis in mice. 
(A) Tumor growth curve. RCA cells expressing Tet-shRNA Ajuba and shRNA-resistant 
wild type Ajuba or Ajuba-2A were subcutaneously inoculated into athymic nude mice 
(Ajuba-WT on the left flank and Ajuba-2A on the right flank) and the mice were kept on 
doxycycline (0.5mg/ml) in their drinking water throughout the experiment. Two of ten mice 
did not form visible tumors (both left and right sides) and were excluded from the analysis. 
Therefore, the tumor volume at each point was the average of 8 tumors. The p values are 
also shown. **, p<0.01;*, p<0.05 (t test). (B) The largest four tumors in each group were 
excised and photographed at the endpoint. C, hematoxylin and eosin (H&E) and CDC25C 
IHC staining in tumors shown in B. (D) Western blotting analysis with tumor samples from 
B. (E-H) The mRNA levels of Ajuba in normal colon and colon tumors from public data 
sets. Data were mined from Oncomine.org. The original studies were as follows: Refs. 
[49](E), [50](F), [51](G), and [52] (H).Tumors, colorectal carcinoma; CA, colorectal 
adenocarcinoma.   
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CHAPTER 2: MST2 PHOSPHORYLATION AT SERINE 385 IN MITOSIS 
INHIBITS ITS TUMOR SUPPRESSING ACTIVITY* 
  
                                               
* The material presented in this chapter was previously published: Chen et al. Cell Signal 
2016; 28(12): 1826-1832. 
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ABSTRACT 
Mammalian sterile 20-like kinase 1/2 (MST1/2) are core tumor suppressors in the 
Hippo signaling pathway. MST1/2 have been shown to regulate mitotic progression. Here, 
we report a novel mechanism for phospho-regulation of MST2 in mitosis and its biological 
significance in cancer. We found that the mitotic kinase cyclin-dependent kinase 1 (CDK1) 
phosphorylates MST2 in vitro and in vivo at serine 385 during antimitotic drug-induced 
G2/M phase arrest. This phosphorylation occurs transiently during unperturbed mitosis. 
Mitotic phosphorylation of MST2 does not affect its kinase activity or Hippo-YAP signaling. 
We further showed that mitotic phosphorylation-deficient mutant MST2-S385A possesses 
higher activity in suppressing cell proliferation and anchorage-independent growth in vitro 
and tumorigenesis in vivo. Together, our findings reveal a novel layer of regulation for 
MST2 in mitosis and its role in tumorigenesis.  
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2.1. Introduction 
Mammalian sterile 20-like kinase 1/2 (MST1/2) are protein kinases that belong to the 
serine/threonine kinase family (MST1 and MST2 are also called STK4 and STK3, 
respectively). MST1/2 are the core components of the Hippo pathway and transduce their 
kinase activity mainly through directly phosphorylating large tumor suppressor 1/2 
(LATS1/2) [2, 5]. Once phosphorylated and activated, LATS1/2 subsequently 
phosphorylate and inhibit the downstream effectors Yes-associated protein (YAP) and 
transcriptional co-activator with PDZ binding domain (TAZ) [2, 5, 6, 8]. Neither MST1 nor 
MST2 alone is required for embryonic development, but double knock out of MST1/2 mice 
exhibit early embryonic lethality, suggesting a redundant and overlapping function 
between MST1 and MST2 [53]. Recent studies using conditional MST1/2 knockout animal 
models demonstrated that MST1/2 function as tumor suppressors [53-56]. In addition to 
their role as tumor suppressors in the Hippo signaling pathway, MST1/2 also 
phosphorylate several other proteins to exercise their functions in various cellular 
processes, mainly in cell proliferation and apoptosis [57]. 
 Mitotic aberration-induced genomic or chromosome instability is characteristic of 
human malignancy [44, 58]. Several recent studies have shown that MST1/2 are important 
regulators for the mitotic machinery. MST1 phosphorylates and inhibits Aurora B kinase 
activity and is required for accurate kinetochore-microtubule attachment [59]. PLK1 (Polo-
like kinase 1) directly phosphorylates MST2 (possibly MST1 as well) in mitosis and this 
phosphorylation allows Nek2A kinase activity to promote centrosome disjunction [60]. 
These studies suggest that MST1/2 function as tumor suppressors through dysregulation 
of mitosis. 
We have recently shown that several upstream regulators (KIBRA and Ajuba) [30, 31, 
61] and downstream effectors (YAP and TAZ) [12, 13] of the Hippo pathway are 
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phosphorylated during mitosis. During these previous studies, we found that the Hippo 
core kinase MST2 is also phosphorylated during antimitotic drug-induced G2/M phase 
arrest. In this report, we further characterized the phospho-regulation of MST2 in mitosis 
and examined the functional significance of the phosphorylation. Our data showed that 
mitotic phosphorylation inhibits MST2 tumor suppressing activity. 
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2.2. Materials and Methods 
2.2.1. Expression constructs, cell culture and transfection 
Flag-MST2 has been described [32]. Point mutations were generated by the 
QuikChange Site-Directed PCR Mutagenesis Kit (Stratagene) and verified by sequencing. 
HEK293T, HEK293GP, and HeLa cell lines were purchased from American Type Culture 
Collection (ATCC) and cultured as ATCC instructed. Attractene (Qiagen) was used for 
transient overexpression of proteins in HEK293T and HEK293GP cells following the 
manufacturer's instructions. SiRNA oligos were purchased from Dharmacon (the target 
sequences were: siMST2-1: CCACAAGCACGA TGAGTGA; siMST2-2: 
GCCCATATGTTGTAAAGTA; siMST2-3: GAACTTTGGTCCGATGATT) and transfected 
with HiPerfect reagent from Qiagen (at the final concentration of 40 nM). Transient 
transfections were done with Attractene reagent (Qiagen) following the manufacturer's 
instructions. Nocodazole (100 ng/ml for 16h) and Taxol (100nM for 16h) (Selleck 
Chemicals) were used to arrest cells in G2/M phase. VX680 (Aurora-A,-B, -C inhibitor), 
BI2536 (PLK1 inhibitor), Purvalanol A (CDK1/2/5 inhibitor), SB216763 (GSK-3 inhibitor) 
and MK2206 (Akt inhibitor) were also from Selleck Chemicals. RO3306 (CDK1 inhibitor) 
was from ENZO Life Sciences. Kinase inhibitors for MEK-ERK (U0126) and p38 
(SB203580) were from LC Laboratory. All other chemicals were either from Sigma or 
Thermo Fisher. 
2.2.2. Tet-On-inducible expression system 
The MST2 or MST2-S385A mutated cDNA was cloned into the Tet-All vector [36] to 
generate Tet-On-inducible overexpression constructs. Retrovirus packaging, infection, 
and subsequent selection were done as we have described previously [62]. The 
transduced cells were selected with neomycin (G418) (400 μg/ml) to establish pooled cell 
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lines. Cells were maintained in medium containing Tet system-approved fetal bovine 
serum (Clontech Laboratories).  
2.2.3. Recombinant protein purification and in vitro kinase assay  
GST-tagged MST2 or MST2-S385A (cloned in pGEX-5X-1) was bacterially expressed 
and purified on GSTrap FF affinity columns (GE Healthcare) following the manufacturer's 
instructions. GST-MST2 (1 μg) was incubated with 5–10 U recombinant CDK1/cyclin B 
complex ( New England Biolabs ) or 50-100 ng CDK1/cyclin B (SignalChem) in kinase 
buffer (New England Biolabs) in the presence of 5 μCi γ- 32P-ATP (3000 Ci/mmol, 
PerkinElmer ) as we previously described [15]. Active CDK2, CDK5, p38, JNK1, JNK2, 
MEK1, ERK1, and PLK1 kinases were also purchased from SignalChem.  
2.2.4. Antibodies 
Rabbit polyclonal phospho-specific antibodies against human MST2 S385 were 
generated and purified by AbMart. The peptide used for immunizing rabbits was KRNAT-
pS-PQVQR. The corresponding non-phosphorylated peptide was also synthesized and 
used for antibody purification. Anti-β-actin (SC-47778) and anti-cyclin B (SC-752) 
antibodies were from Santa Cruz Biotechnology. Glutathione S-transferase (GST) (A190-
122A), Mst1 (A300-465A), Mst2 (A300-467A), and Lats1 (A300-478A) antibodies were 
from Bethyl Laboratories. MST2 antibodies from Cell Signaling Technology (3952) were 
also used. Phospho-Histone H3 Ser10 (3377), phospho- YAP Ser127 (4911), phospho- 
Lats1 Ser909 (9157), phospho-Lats1 Ser1079 (8654), Phospho-MST1(Thr183)/MST2(Thr180) 
(3681), and cleaved caspase 3 (9664) antibodies were also from Cell Signaling 
Technology. Anti-PLK1 antibodies were from Biolegend (667701).Phospho-T210 PLK1 
antibodies were purchased from BD Bioscience (558400).  
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2.2.5. Phos-tag and Western blot analysis 
Phos-tag™ was obtained from Wako Pure Chemical Industries, Ltd. (304-93521) and 
used at 20 μM (with 100 μM MnCl2) in 8% SDS-polyacrylamide gels as we previously 
described [61]. Western blotting, immunoprecipitation, and lambda phosphatase 
treatment assays were done as previously described [31, 34]. 
2.2.6. Cell proliferation and colony formation assays 
For cell proliferation assays, cells (50,000/well) were seeded in a 6-well plate in 
triplicate. Cells were counted by a hemacytometer. Colony formation assays in soft agar 
were performed as described [32]. Cells (5000/well) were seeded in a 6-well plate and 
colonies were counted by ImageJ online. 
2.2.7. Animal studies analysis 
For in vivo xenograft studies, 2.0 X 106 HeLa cells expressing Tet-All-MST2 or Tet-All-
MST2-S385A (non-phosphorylatable mutant) were subcutaneously injected into flanks 
(both left and right) of 6-week-old male athymic Ncr-nu/nu nude mice (Harlan). Five 
animals were used per group. Tumor sizes were measured every four days using an 
electronic caliper starting at 10 days after injection. Tumor volume (V) was calculated by 
the formula: V = 0.5 X length X width2 [32]. The animals were housed in pathogen-free 
facilities. All animal experiments were approved by the University of Nebraska Medical 
Center Institutional Animal Care and Use Committee. 
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2.2.8. Statistical analysis 
Statistical significance was analyzed using a two-tailed, unpaired Student's t-test. 
Pearson Chi-Square analysis was used to determine the statistical significance in Fig. 2-
6C. 
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2.3. Results 
2.3.1. MST2 is phosphorylated during antimitotic drug-induced G2/M arrest 
Using a Phos-tag SDS-polyacrylamide gel system, we recently examined the 
phosphorylation status of the Hippo pathway proteins during G2/M arrest induced by Taxol 
or Nocodazole. During these experiments, we found that MST2, but not MST1, was 
upshifted on a SDS-polyacrylamide gel during G2/M arrest (Fig. 2-1A, B) [61]. Lambda 
phosphatase treatment largely abolished the mobility upshift of MST2, suggesting that 
MST2 is phosphorylated during G2/M arrest (Fig. 2-1A). The phosphorylation on Thr183-
MST1 (Thr180-MST2) in the activation loop was not altered under these conditions (Fig. 2- 
1B).  
2.3.2. Identification of the corresponding kinase for MST2 phosphorylation 
We used various kinase inhibitors to identify the candidate kinase for MST2 
phosphorylation. Inhibition of p38 kinase (with SB203580), JNK1/2 (with SP600125), 
MEK-ERK (with U0126), Akt (with MK-2206), PLK1 (with BI2536), Aurora-A, -B, -C (with 
VX680) or GSK-3 (with SB216763) failed to alter the mobility/phosphorylation of MST2 
during G2/M arrest (Fig. 2-1C, lanes 5-11). These inhibitors are effective under the 
conditions used [12, 63]. Interestingly, treatments with RO3306 (CDK1 inhibitor) or 
Purvalanol A (CDK1/2/5 inhibitor) almost completely reverted the mobility 
shift/phosphorylation (Fig. 2-1C, lanes 3-4). These data suggest that CDK1 is likely the 
corresponding kinase for MST2 phosphorylation induced by Taxol or Nocodazole 
treatment. 
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2.3.3. CDK1 phosphorylates MST2 in vitro 
Next, we performed in vitro kinase assays with bacterially purified MST2 proteins as 
substrates to determine which kinase can directly phosphorylate MST2. Fig. 2-2A shows 
that purified CDK1/cyclin B kinase complex robustly phosphorylated GST-MST2 proteins 
in vitro (Fig. 2-2A). No or very mild phosphorylation was detected when CDK2, CDK5, 
p38, JNK1, JNK2, MEK1, or ERK1 kinase was used in these assays, though these kinases 
recognize the same consensus sequence as CDK1 kinase. These results indicate that 
CDK1 specifically and directly phosphorylates MST2 in vitro. 
2.3.4. CDK1/cyclin B complex phosphorylates MST2 at S385 in vitro  
CDK1 phosphorylates substrates at a minimal proline-directed consensus sequence 
[40]. MST2 only contains a total of 2 S/TP motifs (Ser107 and Ser385) and Ser107 also exists 
in MST1. Therefore, Ser385 was chosen for further investigation. Interestingly, mutating 
Ser385 to alanine completely abolished the 32P incorporation in GST-MST2, suggesting 
that Ser385 is the main CDK1 site in MST2 in vitro (Fig. 2-2B). A recent report showed that 
MST2 is also phosphorylated by the mitotic kinase PLK1 [60]. Consistent with that study, 
we confirmed that MST2 is also a suitable substrate for PLK1 (Fig. 2-2C); however, 
mutating Ser385 to alanine failed to significantly reduce the phosphorylation of MST2 
mediated by PLK1 (Fig. 2-2C). These observations suggest that PLK1 and CDK1 
phosphorylate different sites in MST2 in vitro. 
We have generated phospho-specific antibodies against Ser385. In vitro kinase assays 
confirmed that CDK1 readily phosphorylates MST2 at Ser385 (Fig. 2-2D). Mutating Ser385 
to alanine abolished the phosphorylation, confirming the specificity of our antibody (Fig. 
2-2D). These data indicate that CDK1 phosphorylates MST2 at Ser385 in vitro. 
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2.3.5. CDK1 phosphorylates MST2 at S385 in cells  
Next, we explored whether this phosphorylation occurs in cells. Taxol treatment 
significantly increased the phosphorylation of MST2 Ser385 (Fig. 2-3A). Addition of 
RO3306 or Purvalanol A, but not the PLK1 kinase inhibitor BI2536, greatly inhibited MST2 
Ser385 phosphorylation, suggesting that these antibodies specifically recognize 
phosphorylated MST2 and that phosphorylation of MST2 Ser385 is CDK1 kinase 
dependent (Fig. 2-3A). As expected, the signal of MST2 Ser385 was significantly reduced 
in MST2 knockdown cells (Fig. 2-3B). Using immunoprecipitated samples, we further 
demonstrated that MST2 is phosphorylated on Ser385 during Taxol-induced G2/M in a 
CDK1-dependent manner (Fig. 2-3C). 
2.3.6. MST2 phosphorylation on Ser385 occurs during normal mitosis  
To determine whether phosphorylation of MST2 Ser385 occurs during normal mitosis, 
a double thymidine block and release method was used [38]. Fig. 2-3D shows that the p-
MST2 S385 signal was significantly increased in cells after 11 h of being released from 
double thymidine block (Fig. 2-3D). A significant portion of cells is in mitosis, as revealed 
by increased cyclin B levels (Fig. 2-3D). These results indicate that the phosphorylation of 
MST2 S385 occurs dynamically during normal mitosis. 
2.3.7. Mitotic phosphorylation of MST2 does not impact Hippo-YAP activity 
MST2 is a core kinase in the Hippo-YAP signaling. We first tested whether this 
phosphorylation affects its kinase activity. The non-phosphorylatable (MST2-S385A) 
mutant has similar basal kinase activity revealed by phosphorylation at T180 as wild type 
MST2 (Fig. 2-4A), suggesting that S385 phosphorylation of MST2 does not impact its 
kinase activity. As expected, YAP S127 (a major phosphorylation site mediated by 
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LATS1/2 kinases) phosphorylation was significantly increased upon MST2 
overexpression [32, 62]. However, ectopic expression of MST2-S385A had similar effects 
as wild type MST2 on YAP S127 phosphorylation (Fig. 2-4B). We further established 
doxycycline-induced MST2 or MST2-S385A in HeLa cells, and in the presence of 
doxycycline, both wild type MST2 and MST-S385A were modestly induced at a similar 
level (Fig. 2-4C). No significant changes were detected in the Hippo-YAP signaling activity 
under these conditions (Fig. 2-4C). These observations suggest that phosphorylation of 
MST2 at S385 does not affect Hippo-YAP activity. 
2.3.8. The non-phosphorylatable mutant MST2 possesses stronger inhibitory 
activity in cell proliferation and anchorage-independent growth  
Next, we compared the effects from doxycycline-induced MST2- or MST2-S385A-
expressing HeLa cells to determine the biological significance of S385 phosphorylation of 
MST2. Interestingly, overexpression of the MST2-S385A mutant significantly reduced cell 
proliferation when compared to MST2-expressing cells (Fig. 2-5A). Furthermore, MST2-
S385A-expressing cells formed a significantly lower number of colonies in soft agar when 
compared with MST2-expressing cells (Fig. 2-5B, C). These data suggest that mitotic 
phosphorylation inhibits MST2 activity in suppressing cell proliferation and anchorage- 
independent growth. 
2.3.9. The non-phosphorylatable MST2 mutant inhibits tumorigenesis in vivo  
We further evaluated the influence of S385 phosphorylation on tumor growth in 
animals. An equal number of HeLa cells expressing MST2 or MST2-S385A were 
subcutaneously inoculated into immunodeficient mice and tumor size was monitored in 
the presence of doxycycline. Interestingly, in line with the results in Fig. 2-5, tumors from 
mice bearing MST2-S385A-expressing cells were significantly smaller when compared 
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with those from mice injected with wild type MST2- expressing cells (Fig. 2-6A, B). 
Western blotting analysis showed that MST2 (wild type or S385A) expression levels were 
similar in most of these tumors (Fig. 2-6C). Interestingly, expression of MST2-S385A 
induced stronger apoptosis (detected by cleaved caspase 3) when compared with wild 
type MST2 (Fig. 2-6C, Pearson Chi-Square test, p<0.1). These results suggest that 
phosphorylation of MST2 at S385 inhibits its tumor suppressing activity in vivo. 
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2.4. Discussion 
In the current study, we identified a novel phosphorylation site (S385) on MST2 that is 
dynamically/transiently phosphorylated by CDK1 during mitosis. The mitotic 
phosphorylation of MST2 inhibits its tumor suppressing activity without affecting its own 
kinase activity and the Hippo-YAP signaling. Together, we provided a novel layer of 
regulation of MST2 activity in cancer cells.  
MST2 along with WW45 plays a pivotal role in centrosome disjunction. They directly 
interact with NIMA-related kinase Nek2A and recruit it to the centrosome [45]. Specifically, 
MST2 phosphorylates Nek2A and consequently promotes its recruitments to the 
centrosome. Further, the MST2-WW45 complex contributes to the phosphorylation of the 
c-Nap1 and Rootletin (two centrosomal linker proteins) which are major Nek2A 
phosphorylation targets and bridge the gap between the two centrosomes.  Interestingly, 
other Hippo pathway components, such as LATS1/2, Rassf1A and YAP are dispensable 
for Nek2A recruitment [45]. Those phenotypes are compatible with MST2 S385 
phosphorylation. They affect mitosis without impacting Hippo-YAP activity. Whether S385 
phosphorylation of MST2 is involved in this process is still unknown.  
On the other hand, down regulation of MST2 causes chromosome misalignment 
mediated by Aurora B [59]. Besides, MST2 cooperates with its activator, Mob2 and a 
scaffold protein, Furry, to contribute to mitotic activation of NDR1 kinase, thereby 
regulating the precise alignment of mitotic chromosomes [64].   
Taken together, MST2 is essential in centrosome regulation and chromosome 
alignment in mitosis. Future studies are needed to further determine whether S385 
phosphorylation of MST2 contributes to the fidelity of mitosis and how this phosphorylation 
links subsequent tumorigenesis. Our results showed that mitotic phosphorylation of MST2 
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S385 does not impact the LATS and YAP activity and thus, it will be interesting to see 
what the downstream effector of S385 phosphorylation is. 
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Figure 2-1. CDK1-dependentphosphorylation of MST2 duringG2/M arrest.  
(A) HeLa cells were treated with Taxol as indicated and cell lysates were further treated 
with (+) or without (-) λ phosphatase (ppase). Total cell lysates were probed with anti-
MST2 antibody on Phos-tag SDS-polyacrylamide gels. (B) HeLa cells were treated with 
DMSO, Taxol or Nocodazole (Noco). Total cell lysates were probed with the indicated 
antibodies on Phos-tag or regular SDS-polyacrylamidegels. (C) HeLa cells were treated 
with Taxol together with or without various kinase inhibitors as indicated. RO3306 ( CDK1 
inhibitor, 5μM ), Purvalanol A ( CDK1/2/5 inhibitor, 10 μM ), SB203580 ( p38 inhibitor, 10 
μM ), SP600125 ( JNK1/2 inhibitor, 20μM ), U0126 ( MEK-ERK inhibitor, 20 μM ), MK2206 
( AKT inhibitor, 10 μM ), BI2536  ( PLK1 inhibitor, 100 nM ), VX680 (Aurora-A, B, C 
inhibitor, 2 μM), and SB216763 (GSK3 inhibitor, 10 μM ) were used. Inhibitors were added 
1-2h before harvesting the cells (with MG132toprevent cyclin B from degradation and cells 
from exiting from mitosis). Total cell lysates were subjected to Western blotting with the 
indicated antibodies. SE: short exposure; LE: long exposure. 
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Figure 2-2. CDK1 phosphorylates MST2 in vitro.  
(A) In vitro kinase assays with kinases as indicated. (B) In vitro kinase assays with 
CDK1/cyclin B complex using GST-MST2 or GST-MSTS385A proteins as substrates. 
RO3306 (5μM) was used to inhibit CDK1 kinase activity. (C) In vitro kinase assays with 
PLK1 kinase using GST-MST2 or GST-MSTS385A proteins as substrates. (D) In vitro 
kinase assays were done as in B except anti-p-S385 MST2 antibody was used. 
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Figure 2-3. CDK1 mediates the phosphorylation of MST2 S385 in cells.  
(A) HeLa cells were treated with Taxol together with or without various kinase inhibitors 
as indicated. Inhibitors were added 1.5 h before harvesting the cells (with MG132 to 
prevent cyclin B from degradation and cells from exiting from mitosis). Total cell lysates 
were subjected to Western blotting with the indicated antibodies. (B) HeLa cells were 
transfected with scrambled siRNA (control) or siRNA against MST2 for 48h and were 
further treated with (+) or without (-) Taxol for 14h. The total cell lysates were subjected to 
Western blotting with the indicated antibodies. (C) MST2 proteins in HeLa cells were 
immunoprecipitated and the samples were probed with phospho-S385 MST2 and 
subsequent MST2 antibodies. Total lysates before immunoprecipitation were also probed 
with the indicated antibodies. CDK1 inhibitors RO3306 (5 μM) or Purvalanol A (10 μM) 
together with MG132 (25 μM) were added 1.5 h before the cells were lysed. * marks the 
IgG heavy chain. (D) A double thymidine block and release was performed in HeLa cells 
and samples were collected at the indicated time points. The total cell lysates were probed 
with the indicated antibodies. 
 
  
56 
 
  
57 
Figure 2-4. Mitotic phosphorylation of MST2 does not affect the Hippo-YAP 
activity.  
(A) HEK293T cells were transfected with Flag-MST2 or Flag-MST2-S385A as indicated. 
The immunoprecipitates (with Flag antibodies) were probed with the indicated antibodies. 
* marks the IgG heavy chain. WT: wild type. (B) GFP-YAP was co-transfected with Flag-
MST2-WT or Flag-MST2-S385A with or without Flag-LATS2. The cells were harvested at 
48 h post-transfection and the total cell lysates were analyzed by Western blotting with the 
indicated antibodies. (C) Establishment of Tet-On-inducible HeLa cell lines expressing 
vector, MST2-WT, or MST2-S385A. Total cell lysates were harvested from these cell lines 
in the presence of doxycycline (1 μg/ml for 2 days) and were subjected to Western blotting 
analysis. 
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Figure 2-5. MST2-S385A suppresses cell proliferation and anchorage-independent 
growth.  
(A) Cell proliferation assays with HeLa cells-expressing Tet-MST2-WT or Tet-MST2-
S385A. Cells were kept on Tet-approved FBS and doxycycline was added (1 μg/ml) to the 
cells 2 days prior to the experiments. Data were expressed as the mean ± s.d. of three 
independent experiments. **: p < 0.01; *: p < 0.05 (t-test). (B, C) Colony assays in soft 
agar to assess anchorage-independent growth of HeLa cells expressing Tet-MST2-WT or 
Tet-MST2-S385A in the presence of doxycycline. Data were expressed as the mean ± 
s.d. of three repeats (B) and representative images were shown (C). **: p < 0.01 (t-test). 
WT: wild type. 
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Figure 2-6. MST2-S385A suppresses tumorigenesis in mice.  
(A) Tumor growth curve. HeLa cells expressing Tet-MST2-WT or Tet-MST2-S385A were 
subcutaneously inoculated into athymic nude mice (n = 5, on both left and right flanks) 
and the mice were kept on doxycycline (0.5 mg/ml)-containing water throughout the 
experiments. One inoculation (left flank) in the wild type group did not form visible tumor 
and was excluded from the analysis. Therefore, the tumor volume at each point was the 
average of 9 (MST2-WT) or 10 (MST2-S385A) tumors. **: p< 0.01; *: p < 0.05 (t-test). (B) 
The tumors in each group were excised and photographed at the endpoint. (C) Western 
blotting analysis with tumor samples from B. Pearson Chi-Square test showed that it was 
marginally significant between two groups (p < 0.1).wild type. 
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CHAPTER 3: ROLE OF YAP IN PANCREATIC CANCER-ASSOCIATED 
CACHEXIA 
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ABSTRACT 
Cachexia is a wasting syndrome characterized by body weight loss, atrophy of white 
adipose tissue, and systemic inflammation. It frequently occurs in patients of infectious 
diseases, such as AIDS and tuberculosis, or chronic disease, like heart failure, pulmonary 
disease and chronic kidney disease. Most commonly, cachexia is observed in cancer, 
termed cancer-associated cachexia (CAC). Pancreatic cancer has one of the highest 
incidences of cachexia compared to other cancer types. Pancreatic ductal 
adenocarcinoma (PDAC), is one of the devastating diseases that causes a high death rate 
worldwide. Last decade, the Hippo-YAP signaling pathway was discovered and identified 
as a tumor suppressor pathway, via controlling cell proliferation and apoptosis. Recent 
studies indicate that Hippo-YAP signaling plays a critical role in the development of 
pancreatic cancer. However, the underlying mechanism is poorly understood and 
furthermore, little is known whether YAP is involved in pancreatic CAC. To address these 
important questions, we generated a doxycycline-inducible mouse model in which active 
YAP was specifically expressed in the pancreas to explore the role of YAP and underlying 
mechanisms in the development of pancreatic CAC. We observed that pancreatic specific 
activation of YAP in mice leads to pancreatic acinar-to-ductal metaplasia (ADM) in two 
weeks. Moreover, significant body weight loss and food intake decrease were observed 
after YAP induction in the pancreas. Further, we showed that the level of CXCL13 was 
increased in serum of YAP-pancreas mouse model. Thus, our study suggests a potential 
role of the YAP-CXCL13 axis in pancreatic CAC.   
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3.1. Introduction 
It is estimated that half of cancer patients develop cachexia syndrome at their late 
stage with a severe loss of adipose tissue and skeletal muscle mass [65]. Cachexia is 
characterized by body weight loss, atrophy of white adipose tissue, and systemic 
inflammation. Limited treatment is currently available for cancer-associated cachexia 
(CAC), which leads to approximately 20% of total deaths in cancer patients [66]. 
Therefore, new therapeutic targets for CAC prevention and treatment are urgently needed. 
In the past decades, the investigators have searched for potential mediators of CAC 
in hoping to develop therapeutic strategies against tumor induced weight loss and muscle 
atrophy. The loss of body fat seems to arise from the increased lipolysis, not the decreases 
of lipogenesis. This idea was confirmed by the result of elevated level of free fatty acids 
(FFA) and glycerol in cachexia cancer patient plasma, even presented before significant 
weight loss [67]. In addition to lipolysis increase, there is a well-established link between 
cachexia and systematic inflammation. Interleukin 6 (IL-6) acts alone, or correlated with 
other cytokines, as a driver of systematic inflammation in CAC [68]. Circulating levels of 
IL-6 have been shown to correlate with weight loss, as well as survival in cancer patients 
[69]. In an IL-6-proficent murine synergetic model of cachexia, the silencing of IL-6 could 
rescue the cachexia phenotype, including the reduction of loss of fat tissue and 
morphology change of adipose tissue. The anti-IL-6 antibody treatment can protect K5-
SOS cachexia mice model from losing fat, but recent clinical trials of a monoclonal anti-
IL-6 antibody in weight-losing lung cancer patients have no significant effect on loss of 
body mass [70, 71]. However, the antibody treatment on patients showed reversal of 
anorexia, fatigue, and anemia [72]. Therefore, additional potential targets for CAC 
treatment is urgently needed. What these targets are and how they contribute to CAC are 
critical subjects for current investigation. 
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Cachexia is associated with multiple type of cancers, particularly the gastrointestinal 
tract cancer and the lung cancer [73]. Among those cancer types, PDAC has the highest 
incidence of cancer cachexia and patients experience the greatest degree of weight loss 
and shorter survival time [74]. Pancreatic intraepithelial neoplasia (PanIN) is responsible 
for the development of pancreatic cancer. The origin of the duct cell in the PanIN-PDAC 
progression model is compatible with the concept of acinar to ductal metaplasia (ADM) 
preceding the generation of the small ducts [75]. 
The Hippo-YAP signaling pathway was originally discovered in Drosophila and plays 
an important role in tumorigenesis by regulating cell proliferation and apoptosis [2]. Later 
studies showed that this pathway is highly conserved in mammals [76, 77]. The classic 
pathway in mammals consists of a series of kinases cascade. The core components of 
the Hippo pathway contain kinases MST1/2 (mammalian sterile-20 like kinases1/2) and 
LATS1/2 (large tumor suppressor 1/2), with two scaffold proteins Sav (Protein Salvador 
Homolog 1) and Mob1 (Mps one binder 1). MST1/2 directly phosphorylates LATS1/2 to 
activate LATS1/2, which subsequently phosphorylate and inhibit the downstream effector 
YAP (yes-associated protein) and TAZ (transcriptional co-activator with PDZ binding 
domain). Without the inhibition of Hippo signaling, YAP/TAZ can translocate from 
cytoplasm to nucleus. After binding with transcription factors, transcription of target genes 
will be induced to promote cell proliferation and inhibit apoptosis [7]. Studies from mouse 
models and cancer patients confirmed/demonstrated the oncogenic role of YAP in 
tumorigenesis. For example, overexpression of YAP specifically in liver is sufficient to 
promote hepatocellular carcinoma within three months [32]. Half of aged prostate-specific 
YAP transgenic mice are able to develop prostate tumors compared with no tumor formed 
in the wildtype control [78]. These mouse model studies suggest that YAP plays an 
important role in cancer development. 
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Recent studies suggested that YAP also plays significant role in the development of 
pancreatic cancer. In our previous study, upregulation of YAP in pancreatic cells can 
promote pancreatic cancer cell migration and invasion in vitro [79]. Additionally, 
hyperactive YAP in pancreatic cell not only promotes anchorage-independent growth in 
vitro, but also drives tumorigenesis in xenograft mice [79]. Furthermore, Kapoor et al. 
showed that YAP activation can maintain tumor growth in Kras (G12D)-driven PDAC 
model upon KRAS extinction [80]. These lines of evidence indicate that the transcriptional 
co-activator YAP plays an important role in pancreatic cancer development. We further 
explore the role of YAP in PDAC by generating intact transgenic animals, which was the 
first transgenic animal model expressing hyperactive YAP specifically in pancreas. Our 
study showed that the YAP-pancreas mouse not only initiated ADM, but also caused 
severe weight loss and food intake reduction. Further, we observed highly elevated serum 
level of CXCL13 in YAP-pancreas mouse, indicating the potential role of this cytokine in 
cachexia development.  
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3.2. Materials and Methods 
3.2.1. Generation of mouse strains 
Genetically engineered mouse strains TetO-YAPS127A [81], Ptf1α-Cre (Mutant Mouse 
Resource & Research Centers) and Rosa-LSL-rtTA (Jackson Lab) were interbred to 
generate all experimental colonies (Fig 3-1). All the experimental animals were maintained 
on mixed background in pathogen-free conditions at University of Nebraska Medical 
Center (UNMC). Mice were fed with doxycycline water (Doxycycline Hyclate, Sigma-
Aldrich D9891, 0.2mg/ml in 25mg/ml sucrose) to induce active YAP expression specifically 
in pancreas. All manipulations were approved under UNMC Institutional Animal Care and 
Use Committee (IACUC) under protocol number 12-044. 
3.2.2. Cachexia phenotype observation/measurement 
Each group (control and YAP transgenic) has equal amount (n=3) of mice which were 
housed in the cage with same size. Total body weight was measured at time point of 1 
week and 8 weeks after Dox induction. For Food intake measurements, equal amount of 
food tablets was dispensed to each group at the beginning of the designed week. The 
weight of given food tablets were measured same time everyday within the designed week. 
Average food intake of each mice within the week were calculated. 
3.2.3. Immunohistochemistry (IHC) Staining 
Tissues were fixed in 4% formalin overnight and embedded in paraffin. The unstained 
slides were deparaffinized in xylene and hydrated gradually. The hydrated slides were 
treated with standard citrate or tris-EDTA retrieval buffer for 30 min at 95°C.  After 
incubation overnight with the primary antibodies at 4°C, the slides were incubated with 
biotinylated secondary antibodies (VECTASTAIN Elite ABC HRP Kit, PK-6100, Vector 
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Laboratories Ltd.) for 30 min at room temperature. Antibody labeling was visualized with 
a DAB kit follow the manufacturer’s instructions (ImmPACT DAB Peroxidase HRP 
Substrate, Vector Laboratories Ltd). The antibodies used for IHC analyses are shown 
below. YAP (1:1000 dilution, 4912), Keratin 17/19 (1:200 dilution, 12434), and α-Amylase 
(1:300 dilution, 3796) were from Cell Signaling Technology. Ki67 (1:400 dilution, PA5-
16785) is from Thermo Fisher. 
3.2.4. Analysis of secreted cytokines and CXCL13 ELISA measurements 
The mouse blood samples were collected at designed time point. Samples clotted for 2 
hours at room temperature before centrifuging for 20 minutes at 2000 x g. Serum were 
collected for assay immediately or aliquoted and stored at -80°C. Avoid repeated freeze-
thaw cycles. Semiquantitative cytokine detection was performed using Proteome Profiler 
Antibody Arrays for 111 different antibodies (R&D system; ARY028) according to 
manufacturer’s instructions. The CXCL13 level was measured using mouse CXCL13 
ELISA kits (R&D system; MCX130) [71]. 
3.2.5. Statistical analysis 
Data were analyzed via two-tailed and unpaired Student’s t test or ANOVA. P < 0.05 
was considered statistically significant.  
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3.3. Results 
3.3.1. YAP is sufficient to promote ADM in YAP-pancreas model. 
Previous studies have demonstrated in immunodeficiency mice that YAP gain-of-
function can promote pancreatic cancer cell tumorigenesis [79]. However, there is no 
transgenic mouse model available to further explore the role of YAP in pancreatic cancer. 
To determine whether YAP is involved in PDAC oncogenesis, we obtained the following 
mouse strains, TetO-YAPS127A [81], Ptf1α-Cre (Mutant Mouse Resource & Research 
Centers) and Rosa-LSL-rtTA (Jackson Lab) from colleagues (Table 1). Using mouse 
strains above, for the first time, we established pancreas-specific dox-inducible YAP 
overexpression transgenic mouse model (Fig 3-1). PDAC are thought to originate from 
mature acinar cells which will transdifferentiate into ductal-like cells, a process known as 
acinar to ductal metaplasia (ADM). When YAP-transgenic mice (1-month-old) were 
exposed to Dox for 2 weeks, they developed ADM. YAP-overexpressed pancreases were 
distinguishable from wild-type pancreas in overall histology by hematoxylin and eosin 
(H&E), major pancreatic cell lineage markers [including amylase (in acinar cells), 
cytokeratin 19 (CK19; in ductal cell)], and the proliferation marker (Ki67). Generally, the 
H&E staining indicates that most area of wild-type pancreas have normal acinar cell 
presented, while the examination of pancreatic tissues from young YAP-pancreas 
transgenic mice showed abnormal cell morphology (Fig 3-2A). Further, the IHC staining 
showed that YAP overexpression pancreas significantly increased duct-like area (CK19+) 
but have fewer acinar cell area (α-Amylase+) compared with wild-type pancreas (Fig 3-
2B). Additionally, those ductal-like area of YAP-pancreas transgenic mice showed high 
level of YAP and Ki67 expression, indicating that YAP activation promoted cell proliferation 
and ADM in pancreas. (Fig 3-2A). Comparing the size and texture of pancreas in control 
and transgenic mice, the pancreases from the transgenic group were enlarged and of 
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elastic, hard consistency (Fig 3-2C). Those observations indicate that the acinar cells have 
been transdifferentiated into ductal-like cells in YAP-pancreas transgenic mice. These 
results suggest that the specific expression of YAP in pancreas initiates the process of 
ADM, which can finally develop to PDAC. 
3.3.2. The YAP-pancreas model has cachectic phenotype. 
Cachexia is a wasting syndrome characterized by body weight loss, atrophy of white 
adipose tissue, and systemic inflammation [67, 72, 82]. Besides the ADM, we also 
observed cachectic phenotype on the YAP-Pancreas model.  After being exposed to dox 
for 8 weeks, the 3-month-old YAP-pancreas transgenic model displayed a loss of 15% to 
30% of total body weight (Fig 3-3A).  Food intake was decreased in both female and male 
transgenic mice, (Fig 3-3B, 3C). At necropsy, YAP-pancreas model exhibited massive fat 
atrophy, as evidenced by almost complete loss of gonadal fat (Fig 3-3D). Histological 
examination of gonadal fat revealed the presence of abundant islets composed of small 
adipocytes with big nuclei and multilocular cytoplasm (Fig 3-3E). These data indicate that 
YAP overexpression in pancreas has the potential to promote CAC. 
3.3.3. Association between YAP and CXCL13 in pancreatic CAC. 
Serum levels of many cytokines and their soluble receptors are manipulated in diverse 
cancer types [83]. The mutual effect between cancer cell and its microenvironment can 
induce further production and release of cytokines. Several cytokines including TNF–α, 
IL-6 have been reported in facilitating a cachectic state [83, 84]. According to known 
characteristics of CAC and our results, we expect that high level of YAP in pancreas tumor 
will stimulate the induction of tumor-derived cytokines (tumorkines). Proteome Profiler 
Mouse Cytokine Array Kit (R&D) was applied to detect the level of 111 cytokines with 
single plasma sample (Fig 3-4A). We found that the level of several cytokines 
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(CCL17/TARC 2, CHI3L1 , CXCL13, CXCL16 , LDL R , Lipocalin-2/NGAL, Pentraxin 
2/SAP 2 and Pentraxin 3/TSG-14) were significantly elevated after YAP induction (Fig 3-
4A, 4B). Further, we examined the serum level of CXCL13 in YAP-pancreas model and 
control mice with both 1 week and 1 month dox induction via CXCL13 ELISA kit. The 
upregulation of CXCL13 in the YAP-pancreas model was confirmed (Fig 3-4C).   
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3.4. Discussion 
Recent studies demonstrated that YAP gain-of-function promotes pancreatic cancer 
cell tumorigenesis in vitro and in vivo (both subcutaneously and orthotopically) [79, 80]. 
We then established genetically engineered mouse model of pancreas-specific YAP 
overexpression. In this study, the genetic mouse model we generated displayed ADM and 
cachectic phenotype (Fig 3-2, 3). We further identified the high level cytokine, CXCL13, in 
the mouse model serum via cytokine array (Fig 3-4). The role of CXCL13 in pancreatic 
cancer and cachexia will be determined in future study.   
CXCL13 is a small cytokine belonging to the CXC chemokine family, also known as B 
cell-attracting chemokine 1 (BCA-1). It is expressed by stromal cells within B-cell follicles 
in secondary lymphoid tissues [85]. Tumor-infiltrating lymphocyte B cells have been 
reported to be prevalent in human pancreatic cancer tissues [86]. B cell infiltration was 
detected by Pylayeva-Gupta et al in human PanIN and Kras-driven pancreatic cancer 
model [87].  This group further showed implanted pancreatic ductal epithelial cells 
expressing oncogenic KrasG12D into wild-type pancreata induced B cells accumulation 
in the regions of neoplastic lesions. Besides, the implantation using mice lacking B cells 
(μMT mice) had reduced tumor growth compared with tumors grown in wild-type mice. 
Meanwhile, the anti-CXCL13 treatment can also reduce tumors grown in implantation [87].  
These studies identified a B-cell subset that infiltrates into pancreas during early neoplasia 
and is essential for pancreatic tumorigenesis.  
To date, the role of Tumor-infiltrating lymphocytic B cells (TIL-Bs) in PDAC has not 
been widely investigated. Based on recent publications, the infiltration of B cell supports 
pancreatic tumorigenesis through multiple mechanisms, including suppression of other 
immune cells in the tumor microenvironment and promoting pancreatic cancer cell 
proliferation. Inhibition of B-cell infiltration into the tumor, inhibition of B-cell activity, or 
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simple depletion of B cells using a specific mAb significantly reduced tumor progression 
[71, 86]. A clinical study showed that the serum level of B cell-activating factors in 
pancreatic cancer patients is associated with survival, and maturation of B cells was 
significantly higher in pancreatic cancer patients than in healthy subjects [88].  
The Hippo-YAP signaling pathway was originally discovered in Drosophila and plays 
an important role in tumorigenesis by regulating cell proliferation and apoptosis [2]. Both 
in vitro cell study and in vivo immunodeficiency mice study showed that the loss of 
LATS1/2 promoted cell proliferation and tumor survival. However, the loss of LATS1/2 
suppressed tumor growth in animal with intact immune system which demonstrates its 
ability to stimulate an immune response leading to the destroying of cancer cells [89]. 
However, Guo et al reported later that activation of YAP in tumor-initiating cells (TICs) 
recruits macrophage to small foci of altered hepatocytes. The recruitment is mediated by 
secreted chemokine CCL2 and growth factor CSF1 induced by YAP-TEAD transcriptional 
complex. Elimination of TIC-associated macrophages (TICAMs) impede tumorigenesis 
[90]. Interestingly, YAP mediates myeloid-derived suppressor cells (MDSC) infiltrating to 
prostate tumor via activation of CXCL5-CXCR2 signaling. The infiltrated MDSC promotes 
prostate tumor progression [91]. The role of Hippo pathway in cancer immune is still under 
debate. Based on published discoveries, the activation of its downstream effector YAP or 
knock-out of its upstream kinase will induce immune response via different mechanisms 
depending on experimental models. Meanwhile, the activity of YAP was recently reported 
to be regulated by metabolic pathways, such as aerobic glycolysis and mevalonate 
synthesis [10, 92, 93]. In the meantime, YAP can reprogram metabolism to enable liver 
growth [93]. Those discoveries demonstrated an indispensable role of YAP in metabolism 
regulation which is a key step in cachexia development.   
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However, the dysregulation of metabolism can perturb host immune to control cancer 
development. Several studies have demonstrated that glucose utilization of TILs may be 
impaired by glycolytic activities of cancer cells [94, 95]. Moreover, glucose is a critical 
substrate for T lymphocytes [96]. The demand for glucose supply is altered when Naïve T 
cell differentiates into effector T cells, which rely on a high intake of glucose to support 
proliferation and effector functions, such as cytotoxicity and cytokine production [97].  The 
role of CXCL13 in the network of YAP, cancer immune and cachexia is poorly understood. 
We speculate that the secreted CXCL13 in the YAP-pancreas model may induce immune 
cell infiltration to pancreatic microenvironment leading the initiation of pancreatic cancer 
as well as pre-cachexia. Future studies will be focusing on two aspects. Firstly, we will 
determine whether CXCL13 is a direct target of YAP. Secondly, how CXCL13 affects 
pancreas microenvironment and its role in pancreatic CAC will be determined.  Unveiling 
the underline mechanism will lay a solid foundation in translating a new approach for 
immunoprevention in pancreatic CAC.   
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Figure 3-1. Generation of inducible pancreas-specific YAP overexpression. 
(A). Schematic representation of approaches in generating transgenic mice. The 
pancreas-specific Cre recombinase (Ptf1α-cre) is used to activate reverse tetracycline 
controlled transactivator (rtTA) in Rosa-LSL-rtTA knock-in mice. When these 2 mouse 
strains are crossed to a tetO-YAPS127A transgenic mice, and when the triple transgenic 
mice are subjected to Dox-induction, YAP can be expressed in a Dox-inducible fashion 
specific in pancreas. (B). Tetracycline-inducible conditional YAP expression system. Dox 
binding to rtTA leads to transcriptional activation of transgene, YAP.  
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Figure 3-2. YAP is sufficient for ADM in YAP-Pancreas model. 
 (A-B) Representative images of H&E, YAP, Ki67, α-Amylase and CK19 IHC staining of 
pancreatic sections from 1-month-old control (CTRL, Ptf1а-Cre; Rosa-LSL-rtTA) and YAP 
transgenic (YAP-tg, Ptf1а-Cre; Rosa-LSL-rtTA;YAPS127A)  with 2 week dox induction. (C) 
Representative pancreas image from mice used in (A).  
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Figure 3-3.  The YAP-Pancreas model has cachectic phenotype.  
(A)Total body weight in YAP-pancreatic model and corresponding littermate controls of 
male and female (dox induction at 3-months age, n =3 per genotype) at the time point of 
8 weeks after dox induction. (B-C) Food intake of mice used in (A). (D) Representative 
macroscopic pictures of control mice and YAP-pancreatic model with 2 weeks of dox 
induction at 1-month age at autopsy. The arrowheads point to normal left gonadal fat in 
control mice. In the YAP-pancreatic model, left gonadal fat (arrowhead) is almost 
completely absent. (E)Representative images of hematoxylin and eosin (H&E) staining of 
gonadal fat in mice from (D).  
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Figure 3-4. CXCL13 is induced by YAP overexpression in pancreas. 
(A) Proteome Profiler Mouse XL Cytokine Array results. CXCL13 dots are marked in red 
box. Other up-regulated factors are marked in blue box.  (B) List of upregulated cytokines 
identified from (A). (C) ELISA measurements of CXCL13 relative protein level in YAP-
pancreas mouse model serum.  
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Table 1. List of genetic mouse strain source. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain symbol Sources 
Ptf1α-Cre Mutant Mouse Resource & Research Centers 
Rosa-LSL-rtTA The Jackson Laboratory  
TetO-YAP(S127A) Harvard University, Dr. Fernando Carmago 
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